This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Endo International Dividendo

Dividendo criteri di controllo 0/6

Endo International does not have a record of paying a dividend.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore	2.2%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Utile per azione	-US$10.41
Previsione del rendimento del dividendo	0%

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Aug 16

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

Jul 15

Endo International: Bankruptcy Seems Like The Only Practical Option

Jun 30

Endo International wins FDA approval for Micafungin new formulation

Jun 17

Endo International plc 2021 Q1 - Results - Earnings Call Presentation

May 07

Radius Health partners with Endo unit for abaloparatide in Canada

Jan 05

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Insufficient data to determine if ENDP.Q's dividends per share have been stable in the past.

Dividendo in crescita: Insufficient data to determine if ENDP.Q's dividend payments have been increasing.

Rendimento dei dividendi rispetto al mercato

Endo International Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di ENDP.Q rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (ENDP.Q)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.3%
Media del settore (Pharmaceuticals)	2.2%
Analista previsionale (ENDP.Q) (fino a 3 anni)	0%

Dividendo notevole: Unable to evaluate ENDP.Q's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Dividendo elevato: Unable to evaluate ENDP.Q's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Distribuzione degli utili agli azionisti

Copertura degli utili: Insufficient data to calculate ENDP.Q's payout ratio to determine if its dividend payments are covered by earnings.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Unable to calculate sustainability of dividends as ENDP.Q has not reported any payouts.

This company listing is no longer active

Endo International Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

Endo International plc to Report Q1, 2024 Results on May 30, 2024

Fourth Amended Reorganization Plan Filed by Endo International plc

Endo International plc to Report Q3, 2023 Results on Nov 06, 2023

Endo International plc, Annual General Meeting, Sep 07, 2023

Endo International plc Launches First Generic Version of Noxafil® (posaconazole) Injection

Endo International plc Announces First Patient Enrolled in Registry of Dupuytren's Contracture

Endo International plc Launches PREVDUO (Neostigmine Mylsulfate and Glycopyrrolate Injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

Two Affiliate Companies Joined Endo International plc Bankruptcy

Endo International plc Announces Asset Impairment Charges for Three Months Ended March 31, 2023

Endo International plc and SMSNA Launches App to Provide Peyronie's Disease Self-Assessment Tool

Nasdaq to Delist Common Stock of Endo International

Endo International Provides Delisting Update

Endo International plc(NasdaqGS:ENDP) dropped from NASDAQ Biotechnology Index

Endo International plc(NasdaqGS:ENDP) dropped from S&P TMI Index

Endo International plc Filed for Bankruptcy

Endo International plc Filed for Bankruptcy

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Second quarter 2022 earnings released: US$8.00 loss per share (vs US$0.044 loss in 2Q 2021)

Endo International sees 23% rise on 3x higher than normal volume

Endo outperforms defying bankruptcy fears and generic entry

Endo weighs bankruptcy filing without opioid settlement - WSJ

Endo International Receives Non-Compliance Notice from Nasdaq

Endo International cools off, giving back some of its 85% Tuesday gain

Endo International plc(NasdaqGS:ENDP) dropped from S&P Pharmaceuticals Select Industry Index

Endo: Stick A Fork In It

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting

Price target decreased to US$2.63

Endo International plc to Report Q1, 2022 Results on May 05, 2022

Edesa Biotech, Inc. Appoints Jennifer M. Chao to its Board of Directors

Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-To-Use Vials

Endo: About As Bad As It Gets

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Endo International plc Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles

Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism

Price target decreased to US$6.17

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year

Investor sentiment deteriorated over the past week

Endo International plc Announces its Qwo (Collagenase Clostridium Histolyticum-Aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.30 loss in 3Q 2020)

Investor sentiment improved over the past week

Endo: A Win In California But Equity Value Still A Question

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to US$6.57

Endo International: Loses Vasostrict Trial

Investor sentiment deteriorated over the past week

Endo International: Hires Restructuring Advisor

Consensus forecasts updated

Endo International: All About Ongoing Litigation

Second quarter 2021 earnings released: US$0.044 loss per share (vs US$0.077 profit in 2Q 2020)

Investor sentiment improved over the past week

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

Investor sentiment deteriorated over the past week

Endo International: Bankruptcy Seems Like The Only Practical Option

Endo International plc(NasdaqGS:ENDP) dropped from Russell 2500 Growth Index

Endo International wins FDA approval for Micafungin new formulation

Chairman Paul Campanelli has left the company

Senior Independent Director Roger Kimmel has left the company

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.69 in 1Q 2020)

Endo International plc Announces Asset Impairment Results for the First Quarter Ended March 31, 2021

Endo International plc 2021 Q1 - Results - Earnings Call Presentation

Chairman exercised options and sold US$1.4m worth of stock

Investor sentiment deteriorated over the past week

Independent Director recently sold US$150k worth of stock

Investor sentiment deteriorated over the past week

Price target raised to US$7.45

Full year 2020 earnings released: EPS US$1.08 (vs US$1.60 loss in FY 2019)

Revenue and earnings beat expectations

Endo International plc Appoints Jennifer M. Chao as Director, Audit Committee and its Compliance Committee

New 90-day high: US$10.02

Price target raised to US$6.91